One Centre Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL500036 Compound in Healthy Volunteers
Latest Information Update: 07 Oct 2019
At a glance
- Drugs CPL 500036 (Primary)
- Indications Huntington's disease; Psychotic disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Celon Pharma
Most Recent Events
- 03 Oct 2019 Status changed from recruiting to completed.
- 22 Mar 2019 New trial record